Article
23 Dec 2025
Mise à jour sur le CEPMB : Entrée en vigueur des Lignes directrices pour le personnel du CEPMB le 1er janvier 2026 et Rapport annuel 2024
AUTHORS CONTENT
Article
23 Dec 2025
PMPRB Update: Guidelines For PMPRB Staff Come Into Effect January 1, 2026; 2024 Annual Report
Article
14 Nov 2025
Huitième anniversaire des modifications majeures apportées au Règlement sur les MB (AC)
Article
14 Nov 2025
Faits saillants du premier semestre 2025 au Canada en matière de la PI en sciences de la vie et de droit règlementaire
Article
13 Oct 2025
Supreme Court Of Canada Reserves Decision On Appeal Relating To The Patentability Of Methods Of Medical Treatment
Article
02 Oct 2025
PM(NOC) Regulations: Eighth-year Anniversary Of Major Amendments
Article
15 Jul 2025
2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law
Article
09 Jul 2025
Finalized PMPRB Guidelines Published
Article
30 Jun 2025
Update On Biosimilars In Canada – June 2025
Article
25 Jun 2025
Health Canada Consultation On Revised Biosimilar Guidance: No Requirement For Comparative Clinical Efficacy And Safety Trials
Article
07 Jan 2025
2024 Highlights In Canadian Life Sciences IP And Regulatory Law
Article
30 Dec 2024
Agile Licensing Amendments Registered
Article
30 Dec 2024
PMPRB Releases New Draft Guidelines For Comment
Article
02 Oct 2024
PM(NOC) Regulations: Seven-year Anniversary Of Major Amendments
Article
30 Aug 2024
Manitoba Last Province To Introduce Biosimilars Initiative, While Ontario Adds Four Drugs To Its Biosimilar Policy
Article
12 Jul 2024
2024 Mid-Year Highlights In Canadian Life Sciences IP And Regulatory Law
Article
01 Apr 2024
Update On Biosimilars In Canada – March 2024
Article
26 Jan 2024
Federal Court Finds PMPRB Reasonably Concluded Galderma's Patent Claiming 0.3% Adapalene "Pertained To" 0.1% Adapalene DIFFERIN
Article
15 Jan 2024
2023 Highlights in Canadian Life Sciences IP and Regulatory Law
Article
02 Jan 2024
Government Of Canada Announces Creation Of Canadian Drug Agency
AWARDS
